J. Shan

发表

Staging of chronic myeloid leukemia in the imatinib era

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006 .

Molecular Responses in Patientswith ChronicMyelogenous Leukemia in Chronic PhaseTreatedwith ImatinibMesylate

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005 .

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, M. Talpaz, 2001, Blood.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

E. Burton, H. Kantarjian, G. Garcia-Manero, 2011, Clinical lymphoma, myeloma & leukemia.

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Susan O'Brien, Jorge Cortes, Rajyalakshmi Luthra, 2005, Clinical Cancer Research.

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Blood.

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

A. Verma, H. Kantarjian, J. Cortes, 2009 .

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2010, Cancer.

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

J. Issa, M. Andreeff, H. Kantarjian, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .